SEC Form 4 · accession 0001209191-15-060908

· CELG

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — see remarks

Period of report

Jul 13, 2015

Accepted (ET)

Jul 15, 2015 · 4:30 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000816284

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jul 13, 2015	M	25,000	$29.75	A	80,532	D
Common Stock	Jul 13, 2015	M	5,156	$25.765	A	85,688	D
Common Stock^F1	Jul 13, 2015	S	30,156	$120.78	D	55,532	D
Common Stock	holding	—	—		—	3,200	I	401(k) Plan

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F3,F2	$29.75	Jul 13, 2015	M	25,000	D	—	Dec 27, 2020	Common Stock	25,000	15,000	D
Stock Option (right to buy)^F3,F2	$25.765	Jul 13, 2015	M	5,156	D	—	Jan 31, 2021	Common Stock	5,156	0	D

F1The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person pursuant to a Rule 10b5-1 plan in multiple transactions at prices ranging from $119.66 to $121.40, inclusive. The reporting person undertakes to provide Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2The option was fully exercisable.
F3The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015).

President, Research and Early Development